Mirati Therapeutics, Inc. Logo Image

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. Banner Image

Most Recent Annual Report

2019 Annual Report and Form 10K

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. has reached its limit for free report views.

Mirati Therapeutics, Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Mirati Therapeutics, Inc.

51-200 Employees
Based in San Diego, California

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. Its clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors indications, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, which is in Phase 1 clinical development for the treatment of patients with non-small cell lung cancer and solid tumors; and Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkins lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol